高尿酸痛风患者血清sICAM-1、IL-6、sCD163水平的变化及临床意义  

Changes and clinical significance of serum sICAM-1,IL-6,and sCD163 levels in patients with hyperuricemia and gout

作　　者：余玲 王秀成 徐娜 张立赟[3] 付文涛 YU ling;WANG Xiu-cheng;XU Na;ZHANG Li-yun;FU Wen-tao(Department of Endocrinology,Nanyang Yuxi Jianhe Hospital,Nanyang 474500,Henan,CHINA;Department of Endocrinology,Nanyang Traditional Chinese Medicine Hospital,Nanyang 473000,Henan,CHINA;Department of Endocrinology,Nanyang First People's Hospital,Nanyang 473000,Henan,CHINA)

机构地区：[1]南阳豫西健和医院内分泌科,河南南阳474500 [2]南阳市中医院内分泌科,河南南阳473000 [3]南阳市第一人民医院内分泌科,河南南阳473000

出　　处：《海南医学》2024年第8期1140-1144,共5页Hainan Medical Journal

基　　金：2020年河南省医学科技攻关计划联合共建项目(编号:LHGJ20200955)。

摘　　要：目的检测高尿酸痛风患者血清可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-6(IL-6)、可溶性单核巨噬细胞血红蛋白清道夫受体(sCD163)水平并探讨其临床意义。方法选取2020年1月至2023年1月南阳豫西健和医院收治的200例高尿酸血症(HUA)患者纳入研究,其中92例痛风患者作为观察组,108例无症状患者作为对照组,所有患者均检测血清sICAM-1、IL-6、sCD163水平及血尿酸含量。比较两组患者的血清sICAM-1、IL-6、sCD163水平及血尿酸含量。采用Pearson相关性、多元线性回归分析血清sICAM-1、IL-6、sCD163水平与血尿酸含量的相关性。采用相对危险度(RR)分析血清sICAM-1、IL-6、sCD16对高尿酸痛风发病风险的影响,绘制受试者工作特征曲线(ROC)评价血清sICAM-1、IL-6、sCD163对高尿酸痛风的诊断价值。结果观察组患者的血清sICAM-1、IL-6、sCD163水平和血尿酸含量分别为(574.26±95.22)ng/mL、(50.12±8.27)ng/L、(825.83±198.22)pg/mL、(582.37±156.92)μmol/L,明显高于对照组的(401.47±42.83)ng/mL、(39.82±6.13)ng/L、(694.28±114.83)pg/mL、(425.77±114.83)μmol/L,差异均有统计学意义(P<0.05);经Pearson相关性分析结果显示,高尿酸痛风患者血清sICAM-1、IL-6、sCD163水平与血尿酸水平呈显著正相关(P<0.05);经线性回归建立回归模型分析结果显示,高尿酸痛风患者血清sICAM-1、IL-6、sCD163水平与血尿酸水平呈极显著相关(P<0.01);HUA患者血清sICAM-1≥483.41 ng/mL、IL-6≥44.70 ng/L、sCD16≥598.93 pg/mL时,高尿酸痛风发病风险分别是血清sICAM-1<483.41 ng/mL、IL-6<44.70 ng/L、sCD16<598.93 pg/mL的5.133倍(95%CI:3.181~8.285)、4.412倍(95%CI:2.820~6.903)、3.600倍(95%CI:2.388~5.428);经ROC分析结果显示,血清sICAM-1、IL-6、sCD163诊断高尿酸痛风的曲线下面积(AUC)分别为0.775、0.731、0.792,进一步分析结果显示,血清sICAM-1、IL-6、sCD163联合诊断AUC为0.940,明显较各时间点单个指标大(P<0.05)。结论高尿酸痛风Objective To detect the levels of serum soluble intercellular adhesion molecule-1(sICAM-1),in-terleukin-6(IL-6),and soluble haemoglobin scavenger receptor(sCD163)in patients with hyperuricemia and gout and to explore their clinical significance.Methods A total of 200 patients with hyperuricemia(HUA)admitted to Nanyang Yuxi Jianhe Hospital from January 2020 to January 2023 were enrolled in the study.Among them,92 patients with gout were selected as the observation group and 108 asymptomatic patients were selected as the control group.The levels of serum sICAM-1,IL-6,sCD163,and serum uric acid were detected and compared between the two groups.Pearson cor-relation and multiple linear regression analysis were used to analyze the correlation between serum sICAM-1,IL-6,sCD163 levels and uric acid levels.Relative risk(RR)analysis was used to analyze the effect of serum sICAM-1,IL-6,sCD16 on the risk of developing hyperuricemia and gout.The receiver operating characteristic(ROC)curve was used to evaluate the diagnostic value of serum sICAM-1,IL-6,sCD163 for hyperuricemia and gout.Results The se-rum levels of sICAM-1,IL-6,sCD163,and uric acid in the observation group were(574.26±95.22)ng/mL,(50.12±8.27)ng/L,(825.83±198.22)pg/mL,and(582.37±156.92)μmol/L,respectively,which were significantly higher than(401.47±42.83)ng/mL,(39.82±6.13)ng/L,(694.28±114.83)pg/mL,and(425.77±114.83)μmol/L in the control group(P<0.05).Pearson correlation analysis showed that the serum levels of sICAM-1,IL-6,and sCD163 in patients with hy-peruricemia gout were significantly positively correlated with the level of uric acid(P<0.05).Linear regression analysis showed that the serum levels of sICAM-1,IL-6,and sCD163 in patients with hyperuricemia and gout were signifi-cantly correlated with the level of uric acid(P<0.01).At serum sICAM-1≥483.41 ng/mL,IL-6≥44.70 ng/L,and sCD16≥598.93 pg/mL in HUA patients,the risk of hyperuricemia and gout was 5.133 times(95%CI:3.181 to 8.285),4.412 times(95%CI:2.820 to 6.903)and 3.600 times(95%CI:2.388

关 键 词：高尿酸血症 痛风 可溶性细胞间黏附分子-1 白细胞介素-6 可溶性单核巨噬细胞血红蛋白清道夫受体 相关性 

分 类 号：R589.7[医药卫生—内分泌]